| Acute Declines in Estimated Glomerular Filtration Rate in Patients Treated With Benazepril and Hydrochlorothiazide Versus Amlodipine and Risk of Cardiovascular Outcomes.J Am Heart Assoc | PMID 39056339PMC11964039 | 2024-Aug-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.J Am Heart Assoc | PMID 39056349PMC11964075 | 2024-Aug-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy, immunogenicity and safety of CoronaVac® in children and adolescents aged 6 months to 17 years: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial.Nat Commun | PMID 39107270PMC11303790 | 2024-Aug-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials.Lancet | PMID 39033766无 PMCID | 2024-Aug-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials.Lancet | PMID 39067461无 PMCID | 2024-Aug-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Monopolar versus bipolar transurethral resection of bladder Tumour: post-hoc analysis of a prospective trial.World J Urol | PMID 39093420PMC11297067 | 2024-Aug-02 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Relationship between NT-proBNP, echocardiographic abnormalities and functional status in patients with subclinical siabetic cardiomyopathy.Cardiovasc Diabetol | PMID 39095808PMC11297788 | 2024-Aug-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Adjusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide and dexamethasone.Haematologica | PMID 38426294PMC11290535 | 2024-Aug-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial.Int J Radiat Oncol Biol Phys | PMID 38521132无 PMCID | 2024-Aug-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Dose-intensified stereotactic body radiotherapy for painful vertebral metastases: A randomized phase 3 trial.Cancer | PMID 38581694无 PMCID | 2024-Aug-01 | 0.95 | The study is a randomized phase 3 trial in oncology patients with vertebral metastases, but it does not meet the key eligibility criteria for this cohort. The intervention is radiation therapy only (no drug), and the primary endpoint is pain score improvement at 6 months, which is not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) and no Kaplan-Meier or HR data are provided for such an endpoint. | 待处理 |
| Effects of cariprazine on reducing symptoms of irritability, hostility, and agitation in patients with manic or mixed episodes of bipolar I disorder.J Affect Disord | PMID 38657773无 PMCID | 2024-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of a single-pill versus free combination of perindopril/indapamide/amlodipine: a multicenter, randomized, double-blind study in Chinese patients with hypertension.J Hypertens | PMID 38660708PMC11216387 | 2024-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial.JAMA Psychiatry | PMID 38691387PMC11063924 | 2024-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Totally laparoscopic versus laparoscopy-assisted distal gastrectomy: the KLASS-07: a randomized controlled trial.Int J Surg | PMID 38716987PMC11325945 | 2024-Aug-01 | 0.93 | 干预为非药物单独策略,未满足药物干预要求。 | 待处理 |
| Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial.Blood | PMID 38717861无 PMCID | 2024-Aug-01 | 0.95 | The report is an original, randomized, phase III trial with a drug intervention, but its primary/key secondary endpoint is health-related quality of life (HRQoL), not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. No Kaplan-Meier survival curves or hazard ratios for time-to-event outcomes are reported or referenced in the abstract. Therefore, it does not meet the requirement for a primary/key secondary time-to-event efficacy endpoint. | 待处理 |
| Exposure-Response and Subgroup Analyses to Support Body Weight-Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-risk Classical Hodgkin Lymphoma.Clin Cancer Res | PMID 38810021PMC11292200 | 2024-Aug-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and Safety of Tofacitinib in Ankylosing Spondylitis by Baseline C-Reactive Protein Level: Post Hoc Analysis of Phase II and Phase III Clinical Trials.J Rheumatol | PMID 38825359无 PMCID | 2024-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy.Endocr Relat Cancer | PMID 38828895PMC11301419 | 2024-Aug-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.N Engl J Med | PMID 38828933无 PMCID | 2024-Aug-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.N Engl J Med | PMID 38828951无 PMCID | 2024-Aug-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy: Post Hoc Analysis of the SCOT Randomized Clinical Trial.JAMA Surg | PMID 38865139PMC11170448 | 2024-Aug-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Worst Itch Numeric Rating Scale for Prurigo Nodularis: A Secondary Analysis of 2 Randomized Clinical Trials.JAMA Dermatol | PMID 38865146PMC11170455 | 2024-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5.J Clin Oncol | PMID 38889373无 PMCID | 2024-Aug-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| F18-Choline PET/CT or MIBI SPECT/CT in the Surgical Management of Primary Hyperparathyroidism: A Diagnostic Randomized Clinical Trial.JAMA Otolaryngol Head Neck Surg | PMID 38900416PMC11190825 | 2024-Aug-01 | 0.95 | The study is a Phase 3 randomized trial with original results, but it is not an oncology study (it focuses on primary hyperparathyroidism). The interventions are diagnostic imaging modalities (F18-choline PET/CT vs. MIBI SPECT/CT), not drugs. The primary endpoint is diagnostic accuracy and biochemical success (normocalcemia), not a time-to-event efficacy endpoint like OS or PFS. | 待处理 |
| Survival in Patients With Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical Trial.JAMA Oncol | PMID 38900435PMC11190833 | 2024-Aug-01 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Long-Term Prospective Outcomes of Intensity Modulated Radiotherapy for Locally Advanced Lung Cancer: A Secondary Analysis of a Randomized Clinical Trial.JAMA Oncol | PMID 38935373PMC11211986 | 2024-Aug-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Vitamin K Antagonist Reversal for Urgent Surgery Using 4-Factor Prothrombin Complex Concentrates: A Randomized Clinical Trial.JAMA Netw Open | PMID 39088218PMC11294963 | 2024-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Olanzapine as Antiemetic Prophylaxis in Moderately Emetogenic Chemotherapy: A Phase 3 Randomized Clinical Trial.JAMA Netw Open | PMID 39106066PMC11304110 | 2024-Aug-01 | 0.95 | The trial meets criteria for being an oncology, human, randomized, Phase 3, drug-intervention, original result report. However, it is ineligible because it lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) as required for the cohort. | 待处理 |
| Adjuvant Everolimus in Non-Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial.JAMA Netw Open | PMID 39106067PMC11304111 | 2024-Aug-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Suvorexant for Reduction of Delirium in Older Adults After Hospitalization: A Randomized Clinical Trial.JAMA Netw Open | PMID 39150711PMC11329875 | 2024-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Promoting Resilience in Stress Management for Adolescents With Type 1 Diabetes: A Randomized Clinical Trial.JAMA Netw Open | PMID 39158914PMC11333977 | 2024-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| GABA Analogue HSK16149 in Chinese Patients With Diabetic Peripheral Neuropathic Pain: A Phase 3 Randomized Clinical Trial.JAMA Netw Open | PMID 39158916PMC11333976 | 2024-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data.J Acquir Immune Defic Syndr | PMID 40788226PMC11195927 | 2024-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Are technology-based health education methods able to reduce oral health inequalities between the sexes in adolescents? A cluster randomized trial.Int J Dent Hyg | PMID 36301013无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The Effect of Vitamin B12 Supplementation on Leukocyte Telomere Length in Mildly Stunted Nepalese Children: A Secondary Outcome of a Randomized Controlled Trial.J Nutr | PMID 37918674无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of presbyopia treatment pilocarpine hydrochloride 1.25% on night-driving performance.Clin Exp Optom | PMID 38044272无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis.J Card Fail | PMID 38065307无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis.Eur Urol Oncol | PMID 38072761无 PMCID | 2024-Aug | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.Eur Urol Oncol | PMID 38143206无 PMCID | 2024-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials.Ophthalmology | PMID 38280653无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Bacillary Layer Detachment in Neovascular Age-Related Macular Degeneration from a Phase III Clinical Trial.Ophthalmol Retina | PMID 38360182无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.Ophthalmology | PMID 38382813无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Compartmental Exudative Dynamics in Neovascular Age-Related Macular Degeneration: Volumetric Outcomes and Impact of Volatility in a Phase III Clinical Trial.Ophthalmol Retina | PMID 38403242无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Evaluating the Efficacy and Safety of Aflibercept Biosimilar (P041) Compared with Originator Product in Patients with Neovascular Age-Related Macular Degeneration.Ophthalmol Retina | PMID 38428459无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term intraocular pressure-lowering efficacy and safety of ripasudil-brimonidine fixed-dose combination for glaucoma and ocular hypertension: a multicentre, open-label, phase 3 study.Graefes Arch Clin Exp Ophthalmol | PMID 38430227PMC11271374 | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).J Eur Acad Dermatol Venereol | PMID 38451052无 PMCID | 2024-Aug | 0.95 | The study is a Phase III randomized controlled trial of a drug (deucravacitinib) for psoriasis (not a malignant neoplasm) and reports on safety/tolerability, not a primary/key secondary time-to-event efficacy endpoint. | 待处理 |
| Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 2-year results from the Japan subgroup of the phase III TENAYA trial.Graefes Arch Clin Exp Ophthalmol | PMID 38483611PMC11271316 | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Upadacitinib Reduces Crohn's Disease Symptoms Within the First Week of Induction Therapy.Clin Gastroenterol Hepatol | PMID 38492903无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study.J Invest Dermatol | PMID 38493933无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Randomized, Controlled Comparison of NCX 470, a Nitric Oxide-Donating Bimatoprost, and Latanoprost in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The MONT BLANC Study.Am J Ophthalmol | PMID 38499140无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |